APA (7th ed.) Citation

SM, H., TA, F., JC, Y., MS, K., J, M., PA, H., . . . SM, S. (2025). Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. Leukemia & lymphoma, 66(6), 1100. https://doi.org/10.1080/10428194.2025.2455489

Chicago Style (17th ed.) Citation

SM, Horwitz, et al. "Results from an Open-label Phase 2a Study of Cerdulatinib, a Dual Spleen Tyrosine Kinase/janus Kinase Inhibitor, in Relapsed/refractory Peripheral T-cell Lymphoma." Leukemia & Lymphoma 66, no. 6 (2025): 1100. https://doi.org/10.1080/10428194.2025.2455489.

MLA (9th ed.) Citation

SM, Horwitz, et al. "Results from an Open-label Phase 2a Study of Cerdulatinib, a Dual Spleen Tyrosine Kinase/janus Kinase Inhibitor, in Relapsed/refractory Peripheral T-cell Lymphoma." Leukemia & Lymphoma, vol. 66, no. 6, 2025, p. 1100, https://doi.org/10.1080/10428194.2025.2455489.